Weight loss due to treatment with metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor analogs can lead to sarcopenia in older patients without adequate exercise. This evidence concerns the gene SLC5A2 and sarcopenia.